Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ESMO 2020 | Summary of the AToM trial

Monika Krzyzanowska, MD, MPH Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada, discusses the AToM trial (NCT02485678). This study is a pragmatic cluster-randomized trial of ambulatory toxicity management in patients receiving adjuvant or neo-adjuvant chemotherapy for early-stage breast cancer. This study evaluated the effectiveness of proactive toxicity management intervention in a care setting. The primary outcome for this study was the mean number of emergency department visits or hospitalizations per patient. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.